NCT06523803

A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

A Phase 1, Open-label, Multicenter Study of ZW171 in Participants With Advanced or Metastatic Ovarian Cancer, Non-small Cell Lung Cancer (NSCLC), and Other Mesothelin Expressing Cancers

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Zymeworks BC Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to find out if ZW171 is safe and can treat participants with advanced (locally advanced \[inoperable\] and/or metastatic) mesothelin-expressing cancers.

Detailed description

Part 1 of the study will evaluate the safety and tolerability of ZW171. Part 2 of the study will evaluate the anti-tumor activity of ZW171 while continuing to evaluate the safety and tolerability.

Conditions

• Mesothelin-expressing Advanced Cancers

Interventions

Type	Name	Description
DRUG	ZW171	Administered per protocol requirements

Timeline

• Start date: 2024-09-30
• Primary completion: 2025-09-30
• Completion: 2025-10-01
• First posted: 2024-07-26
• Last updated: 2025-10-21

Locations

15 sites across 4 countries: United States, Germany, South Korea, United Kingdom

Regulatory

• FDA-regulated drug study